Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,043 people get INO articles and Market Currents by email alert.
Get email alerts on INO »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
PR Newswire (May 10, 2013)
-
-
-
-
-
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
Inovio Biomedical's Innovative Approach to DNA Vaccine DeliveryMike Havrilla • Fri, Dec 14, 2007 -
Inovio’s Delivery Technology Boosts Cancer Vaccine PotencySara Calabro • Thu, May 24, 2007
-
Inovio Biomedical: Shocking Tumor Technology Tempting to Big PharmasAndrew Vaino • Mon, Feb 26, 2007
There are no Transcripts on INO.
-
PR Newswire (May 10, 2013)
-
PR Newswire (Mar 28, 2013)
-
PR Newswire (Mar 18, 2013)
-
PR Newswire (Mar 12, 2013)
-
PR Newswire (Mar 7, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 5, 2013)
-
PR Newswire (Feb 4, 2013)
-
at CNBC.com (Jan 17, 2013)
-
PR Newswire (Dec 20, 2012)
-
PR Newswire (Dec 10, 2012)
-
PR Newswire (Dec 6, 2012)
INO vs. ETF Alternatives
Company Description
Currently, there's no company description for INO.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 14, 9:42 AM Inovio Pharmaceuticals (INO +6.6%) pops after saying its SynCon DNA vaccine for the Marburg and Ebola viruses provides 100% protection against death. (PR) 1 Comment [Healthcare, On the Move]
- Friday, May 10, 4:48 PM Inovio (INO): Q1 EPS of -$0.06 misses by $0.02. Revenue of $1.5M beats by $0.49M. (PR) 2 Comments [Earnings, Breaking News, Healthcare]
- Thursday, April 18, 1:34 PM Inovio Pharmaceuticals (INO +0.4%) says Phase 1 studies of its SynCon universal H1N1 influenza vaccine generated protective antibody levels comparable to a current FDA-approved seasonal influenza vaccine against a currently circulating influenza strain. INO adds that this is the first demonstration of a SynCon influenza vaccine achieving a protective immune response rate comparable to a conventional seasonal vaccine for a circulating influenza strain. 1 Comment [Healthcare]
- Tuesday, April 2, 8:36 AM Inovio (INO) plummets 13.3% after saying that a Phase II trial that tested the use of the company's MedPulser delivery device in conjunction with ChronTech's ChronVac vaccine for hepatitis C failed to show "a statistically significant difference" between the vaccinated and non-vaccinated groups. (PR) Comment! [On the Move, Healthcare]
- Tuesday, March 19, 6:36 AM Inovio Pharmaceuticals (INO): Q4 EPS of $0.00. Revenue of $1.1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, March 7, 8:20 AM Inovio Pharmaceuticals (INO) plummets 20.3% to $0.55 after pricing an offering of 27.4M shares, and warrants to purchase up to 13.69M shares, at a combined price of $0.55/share and related warrant. The warrants are exercisable at $0.7936/share and will expire in 5 1/2 years. The net proceeds of the fundraising are $14M. (PR) 2 Comments [Healthcare, On the Move]
- Friday, January 18, 11:25 AM Inovio Pharmaceuticals (INO +2.8%) bucks a lackluster tape to trade higher after Piper Jaffray initiates coverage with an Overweight. Piper notes the company is developing a novel DNA-based vaccine platform that is demonstrating "provocative" immune responses in early studies against a multiplicity of non-viral oncology targets, as well as several infectious diseases such as HIV, HCV, HPV, and the flu. The firm adds that multiple Phase II catalysts are expected this year in its HCV and leukemia platforms. Comment! [Healthcare, On the Move]
- Friday, January 18, 9:17 AM Geron (GERN) +5.4% after an upgrade to Buy with $3 price target by Piper Jaffray's Charles Duncan. The current price of $1.66 reflects past challenges, he says, but leaves room for substantial upside over the course of the next year. That Geron and INO are buys at Piper while ZIOT and THLD are Holds does not compute, says Dan Rosenblum. Sell-side games, says TheStreet's Adam Feuerstein. 1 Comment [Healthcare, On the Move]
- Wednesday, October 10, 2012, 3:46 PM Inovio Pharmaceuticals (INO +14.8%) pops after announcing Phase I clinical results indicating that its DNA-based synthetic vaccine VGX-3100 is not only capable of boosting immune responses to antigens from high risk types of human papillomavirus infection, but also killing cells changed by the virus into precancerous dysplasias. Comment! [Healthcare, On the Move]
- Tuesday, January 31, 2012, 7:59 AM Shares of Inovio Pharmaceuticals (INO) shoot 23.2% higher in premarket trading after the firm announces that it moved close to a "universal" influenza vaccine after animal studies of its treatment showed positive immune responses and data. The company expects to report human data on the vaccine by the end of Q1. Comment! [Healthcare, On the Move]
- Tuesday, September 13, 2011, 1:08 PM Inovio Pharmaceuticals (INO +7.3%) says early data from a Phase I study assessing its PENNVAX-G global HIV vaccine demonstrated "strong immune responses and safety." Comment! [Healthcare, On the Move]
- Thursday, July 14, 2011, 9:41 AM Inovio Pharmaceuticals (INO +2.7%) gains at the open after announcing Phase I tests on T cell and antibody responses were successful in its clinical study of VGX-3400X, a vaccine to prevent avian H5N1 influenza. Comment! [Healthcare, On the Move]
- Tuesday, July 5, 2011, 8:00 AM Inovio Pharmaceuticals (INO) shoots up 12.3% premarket after announcing its synthetic DNA vaccine protects against HIV in animal testing. Comment! [Healthcare, On the Move]
-
Monday, May 9, 2011, 9:00 AM
Premarket gainers: INO +13%. DTG +9%. BSFT +8%. AFFX +7%. ALKS +6%. EXK +5%. GPL +5%. SYY +5%. ELN +4%. HL +4%. SQNM +3%. CEF +3%. SD +3%.
Losers: ZSL -11%. ZRAN -10%. GKK -8%. IRE -3%. LEXG -3%. Comment! [On the Move] -
Monday, February 7, 2011, 9:00 AM
Premarket gainers: PDE +17%. BEC +10%. PGNX +9%. INO +5%. GLUU +5%. OREX +5%. DHR +5%. EMKR +4%. MGIC +4%. CHK +4%. AIB +4%.
Losers: YONG -10%. WY -5%. SYY -4%. Comment! -
Monday, January 11, 2010, 9:00 AM
Premarket gainers: EPCT +37.5%. EXXI +25%. MMR +21%. ACHN +16%. AIS +9%. PXP +9%. CRBC +8%. VVUS +6%. GSS +6%. VICL +6%. PCX +6%. ACI +5%. SOLF +5%. BCRX +4%. GLW +4%. INO +4%. NGD +4%. HL +4%. AIB +4%. DPTR +4%.
Losers: ASBC -11%. FMX -7%. ARIA -6%. Comment!
-
smokeyRose
All my stocks are Doing well except $CBO $INO (which I am going to Dump, can't take the pain anymore with That one) $ICON while up still - View all 1 replies
-
-
Chemistfrog
$INO traded down due to poor data from collaborator using their own DNA. Updates on the company using their own DNA could really push it up - View all 0 replies
-
VFC's Stock House
$SSH, $INO, $APHY.OB Stock Watch Wednesday, http://bit.ly/cAHZ42 - $SNWV.OB, $ANTB.OB, $TTNP.OB - View all 0 replies
-
- View all 0 replies
-
TruffelPig
Just bought some $INO AH and got a discount......0.52. Weird. Was the only trade. Closed at 0.54. - View all 3 replies
-
Noreika: Do you believe the CEO is really blind to the results of the studies like he says he is? -
TruffelPig: I really don't know. They have a nice pipeline - I know that.
-
TruffelPig
Fute stars in biotech: http://bit.ly/W9bQXv $ECYT $THLD $INO of mine are there. (INO as of tomorrow) - View all 1 replies
-
-
- View all 2 replies
-
Kyle_Ramer: Everywhereman -you seem a little confused to the original constructs of the deal the initial deal -
Everywhereman: Perhaps. But then I am in good company as that is what INO management says. May I inquire as to your source?
-
BioInvestor2013
$INO INOVIO can acquire ChronTech with only 1% of ChronTech outstanding shares !! This is Great !! - View all 0 replies
-
BioInvestor2013
$INO owns 50% of ChronTech !! Kim mentioned that Inovio owns half of Chronvac-C and full rights to Electroporation of the drug !! - View all 0 replies
-
- View all 1 replies
-
workhorse@bps: Here is hoping and I agree, there are a lot of other companies with smaller pipelines and same stage that have larger mrkt cap
LATEST REPLIES
-
smokeyRose
All my stocks are Doing well except $CBO $INO (which I am going to Dump, can't take the pain anymore with That one) $ICON while up still - View all 1 replies
-
-
TruffelPig
Just bought some $INO AH and got a discount......0.52. Weird. Was the only trade. Closed at 0.54. - View all 3 replies
-
Noreika: Do you believe the CEO is really blind to the results of the studies like he says he is?
-
TruffelPig: I really don't know. They have a nice pipeline - I know that.
-
TruffelPig
Fute stars in biotech: http://bit.ly/W9bQXv $ECYT $THLD $INO of mine are there. (INO as of tomorrow) - View all 1 replies
-
-
- View all 2 replies
-
Kyle_Ramer: Everywhereman -you seem a little confused to the original constructs of the deal the initial deal
-
Everywhereman: Perhaps. But then I am in good company as that is what INO management says. May I inquire as to your source?
-
- View all 1 replies
-
workhorse@bps: Here is hoping and I agree, there are a lot of other companies with smaller pipelines and same stage that have larger mrkt cap
-
- View all 4 replies
-
-
-
- View all 4 replies
-
VFC's Stock House: Haha, SmokeyRose - I don't know much more than anyone else, except that $INO is up about twenty five percent this year. Nice. Good luck!
-
-
- View all 7 replies
-
VFC's Stock House: ..put more into any individual investment to where you lose sleep at night. some here, some there...just my opinion.
-
-
- View all 5 replies
-
-
Avoc: The recent drop in INO stockprice is due to a huge fund selling most of their holdings in order to get some money, perhaps due to taxes.
-
- View all 2 replies
-
-
smokeyRose: Like Meatloaf says..... "You took the words Right out of my Mouth"
-
VFC's Stock House
Weekly Stock Watch ... $DNDN, $CPST, $ONCS.OB, $AEZS, $INO, $GE, $BAC ... more ... http://bit.ly/R6JcSY - View all 1 replies
-
-
iadops40
INO looking really good here, deep pipeline http://bit.ly/TmcOwm, and Phase I results for VGX-3100 released today. bullish! - View all 1 replies
-
-
- View all 1 replies
-
-
- View all 3 replies
-
-
-
- View all 2 replies
-
-
